Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q2 FY2021 Earnings Presentation
38 slides from Shilpa Medicare's earnings presentation, Nov 2, 2020
Slide 1: Regulation 30 cover letter to stock exchanges
Shilpa Medicare Limited Corporate & Admin Office: Innovating for "Shilpa House", # 12-6-214/A-l, Hyderabad Road, I affordable healthcare Raichur-584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshilpa.com, Web: www.vbshilpa.com CIN:L85110KA1987PLC008739 Dated 02 nd
Slide 2: Q2 & H1 FY21 Results Presentation
Biological TDS ODF Facility & BANGALORE TO ADD - Bengaluru Dharwad FACILITY PHOTO Q2 & H1 FY21 Results Presentation Shilpa Medicare Limited (SML)
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ mat
Slide 4: Table of Contents
Table of Contents Company Overview 4 Discussion of Select Business Segments 13 Financial Performance 20 To insert picture of Biologicals facility Business Updates 26 Way Forward 32 Annexure 34 3
Slide 5: Company Overview
Company Overview Established Pursuing niche presence in Active growth Pharmaceutical businesses like Ingredients (APIs) Transdermal, Oral Dissolving and Formulations for domestic & Films and Dermatological Robust research Affordable & international Formulations orientation resulting in Effective mar
Slide 6: Established Business Segments
Established Business Segments Description Capacities API Manufacturing API products with highly précised Isolator Technology 9 dedicated Blocks for Oncology & 4 Blocks for Non- Facility is approved by USFDA, WHO-GMP, EUGMP, Oncology TGA, PMDA, KFDA, TPD Multi-product capability for Oncology
Slide 7: Established Business Segments
Established Business Segments Description Capacities Company pursues an aggressive IP strategy for Bio Biologicals & similar and NBE assets Biosimilars 6 out of the top 15 Biological products are in the pipeline 2 Independent lines - single use lines (1,000L Bioreactor each) for production of
Slide 8: Growth Business Segments
Growth Business Segments Description Capacities Company is engaged in R&D in various Dermatological Dermatological products Formulations 2 Products are ready to be filed under which 1 Product is Niche Generic and 1 Product is Niche OTC Plan to launch 1 product in domestic market by June- R&D
Slide 9: Strengths
R&D Competence Technology Edge SML’s Key Strengths Rich Scientific Talent Manufacturing Excellence 8
Slide 10: TD and ODF Research & Development Competence
TD and ODF Research & Development Competence R&D lab equipped with State-of-the-art machines and instruments required for pre-formulation and formulation development of Transdermal System (TDS) / Matrix patches and Oral Disintegrating films (ODF) Healthy generic pipeline of projects including Pa
Slide 11: Technology Edge
State of the art machines and equipment for TDS and ODF dosage forms Fully automated world class ODF and TDS manufacturing Combo facility at Bengaluru based to produce high quality Technology products with German equipments Edge Low waste leading to low COGS Coating Machine Flexibility to in
Slide 12: Rich Scientific Talent
Rich Scientific Current pipe line Talent projects for TDS/ODF for Global market (TDS & ODF) Transdermal system (Complex generics / combination product) development for highly regulated markets Formulation 40+ and Analytical development Oral disintegration film development for highly Scientists regul
Slide 13: Manufacturing Excellence
Manufacturing Excellence Facility Location Facility Type Biologicals Manufacturing plant & R&D Dharwad Facility TDS & ODF Manufacturing Facility & R & D Bengaluru (All segments except Biologics) Raichur Unit I API (Onco – Non-Oncology) India Raichur Unit II API (Onco – Non-Oncology) and R & D API Ja
Slide 14: Discussion of Select Business Segment
Coating Machine Discussion of Select Business Segment 13
Slide 15: Film Formulation – Under Shilpa's Brand
Film Formulation – Under Shilpa’s Brand Methylcobalamin Orally Tadalafil Orally Disintegrating Disintegrating Strips 1500 mcg Strips 5 mg, 10 mg and 20 mg Simethicone Orally Ondansetron Orally Disintegrating Disintegrating Strips 62.5 mg Strips2 mg, 4 mg and 8 mg 14
Slide 16: Green T Film
Green T Film With the launch of ready to dissolve Green Tea, SML forayed into the niche OTC segment SML’s Green T films are patent protected and first of this kind in the world These Green T Films are currently available in Ginger and Lemon flavors SML’s Green T Films are an innovative produ
Slide 17: Vital benefits Green T Film
Vital benefits Green T Film BENEFITS OF SHILPA’S GREEN TEA FILM • Fat burning properties assisting in weight loss • Free Radical Scavengers in the Green tea reduces the chances of cancer occurrence • Boosts metabolism • Reduces hunger • Improves physical performance • Green tea catechin may improve
Slide 18: Green T Films Vs Green Tea Bag
Green T Films Vs Green Tea Bag Advantages of Green Tea Film Disadvantages of Green Tea Bag Completely disintegrates in hot water and does not leave Do not dissolve or disintegrate in hot water and leaves any residues behind residues behind Gives accurate dose as per the label claim Dose may
Slide 19: Green T Film – Social Media Presence
Green T Film – Social Media Presence Shilpa's Green Tea Insta Page shilpaotc.com Shilpa's Green T Film FB page Shilpa's Green Tea Twitter Page Amazon page 18
Slide 20: TDS & ODF Key Highlights
TDS & ODF Key Highlights : Manufacturing Vessels 19
Slide 21: Financial Performance
Slitting Machine Financial Performance 20
Slide 22: Abridged P&L Statement - Standalone
Abridged P&L Statement -Standalone (Rs. In Lakhs) Particulars Q2 FY21 Q2 FY20 Change (%) H1FY21 H1FY20 Change (%) F.Y 2019-20 Total Income (A+B+C+D) 26,269 23,653 11 47,933 39,110 23 80,598 Normalised Total Income (A+B+C+D+E) 27,021 23,897 13 48,949 39,696 23 81,724 Total Revenue from Operations (A+
Slide 23: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated (Rs. In Lakhs) Particulars Q2 FY21 Q2 FY20 Change (%) H1FY21 H1FY20 Change (%) F.Y 2019-20 Total Income (A+B+C+D) 27,934 28,992 (4) 50,181 45,091 11 90,791 Normalised Total Income (A+B+C+D+E) 28,854 29,574 (2) 51,649 45,871 13 92,485 Total Revenue from Operation
Slide 24: Results Snapshot (Standalone)
Results Snapshot (Standalone) Key Highlights Revenue Breakup (In Lakhs) 18000 16509 16000 14120 • API & Formulation revenue growth Y-o-Y 14000 i.e Q2 FY21 v/s Q2 FY20 are 17% and 73% 12000 respectively. 10000 8190 8000 • Service Income in Q2 FY20 includes one 6000 4747 4072 time License revenue of R
Slide 25: Capital Investment & Debt Details - Standalone
Capital Investment & Debt Details - Standalone (Rs. In Lakhs) Particulars As on 30.09.2020 As on 31.03.2020 Capital Investments Fixed Asset Gross Block 77,931 73,392 Tangible Assets (Project Under Progress) 31,647 24,418 Intangible Assets Under Development 14,050 12,863 Total Capital Investment 123,
Slide 26: Historical Revenue Statement – Standalone
Historical Revenue Statement – Standalone Total Revenue –13.66% CAGR in last 3 years (Rs. In Lakhs) 2018 2019 2020 2,332 1,553 2,334 2,553 1,126 3,117 3,027 8,968 3,602 8,909 38,821 16,596 34,817 19,115 36,511 Strong trends in underlying performance ex of CRAMS over the past few years 25
Slide 27: Business Update
Converting Machine Business Update 26
Slide 28: Corporate updates
Corporate updates Future Growth Businesses R&D Facility at Bengaluru is now fully operational Formulations Additionally, the Project work for Ophthalmic Following products were commercialized Line and Pilot Plant is underway Green Tea Film launched in Domestic The Bengaluru center also has
Slide 29: Current Status on USFDA Warning Letter
Current Status on USFDA Warning Letter Shilpa’s Jadcherla Unit was served a Warning Letter from USFDA The Warning Letter acknowledges Shilpa’s responses to the 15 observations listed in Form 483, as well as some of the measures taken by Shilpa to address the concerns raised in the Form 483 As
Slide 30: Message by Dr. Jayant Karajgi – COO (Formulation)
Message by Dr.Jayant Karajgi – COO (Formulation) Commenting on the performance for Q2 FY2021, Dr. Jayant Karajgi , COO (Formulation), Shilpa Medicare Limited (SML), said: “We are pleased to have continued the steady performance and growth in this quarter despite the challenges of working under const
Slide 31: Patents Status as on September 30, 2020
Patents Status as on September 30, 2020 Patents Filings Granted Pending - API 201 37 164 - Formulation 110 14 96 - Films Topical & Transdermal 48 2 46 - Biologicals 8 2 6 - Others 22 1 21 TOTAL 389 56 333 30
Slide 32: Formulation Product Pipeline as on September 30, 2020
Formulation Product Pipeline as on September 30, 2020 Approved Patents Filings (Including Pending Tentative) US ANDA/NDA - On SML’s Name 25 13 12 - On Customer’s Name 18 12 6 TOTAL (In US) 43 25 18 - EU Filing 20 14 6 TOTAL (In US & EU) 63 39 24 31
Slide 33: Way Forward
Quality Control Lab Way Forward 32
Slide 34: Way Forward
Way Forward API Formulations Future Growth Businesses Plans to commercialize Achieved significant progress in two of Diversification in other therapeutic areas like Biologics, 3-4 molecules each year the goals stated in Q1 (expanded portfolio expansion to Transdermal Dosage Forms and geographi
Slide 35: Annexures
Packaging Machine Annexures 34
Slide 36: Historical R&D Expenditure Trends
Historical R&D Expenditure Trends (Rs. In Lakhs) Particulars FY18 FY19 FY20 H1-FY21 Total R&D Expenditure 7,813 8,751 12,883 5,556 R&D Revenue Expenditure 5,386 4,004 6,948 3,643 R&D Intangible Assets 2,427 4,747 5,935 1,914 (incl. CWIP) R&D as a % of Revenue 10% 13% 16% 12% Strong orientation on R&
Slide 37: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.
Slide 38: Thank You
API Facility Temple Photo - Raichur Thank You 37